Feasibility of combination allogeneic stem cell therapy for spinal cord injury: a case report

Ichim, Thomas E.; Solano, Fabio; Lara, Fabian; Paris, Eugenia; Ugalde, Federico; Rodríguez, Jorge Paz; Minev, Boris; Bogin, Vladimir; Ramos, Famela; Woods, Erik J.; Murphy, Michael P.; Patel, Amit N.; Harman, Robert J.; Riordan, Neil H

doi:10.1186/1755-7682-3-30

Cited by 80 publications

(65 citation statements)

References 109 publications

(110 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…24 It is also possible to use these cells for allogenic transplantation as there is little risk of immunological rejection or graft-versus-host reactions. 25 The safety of transplanted unmanipulated autologous bone marrow in subjects with SCI has been reported by Sykova et al 26 However, the authors could not confirm that the observed beneficial effects were due to cellular intervention. 26 Other groups have transplanted enriched or expanded bone marrow mesenchymal stem cells in SCI subjects either alone or in combination with CD34+ cells or GM-CSF.…”

Section: Discussioncontrasting

confidence: 41%

“…26 Other groups have transplanted enriched or expanded bone marrow mesenchymal stem cells in SCI subjects either alone or in combination with CD34+ cells or GM-CSF. 21,25 However, because of various limitations of these studies, the outcomes reported are inconclusive. 2 This study was initially planned to transplant the Ficoll-purified mononuclear cell population as used in other studies.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Autologous bone marrow cell transplantation in acute spinal cord injury—an Indian pilot study

et al. 2015

View full text Add to dashboard Cite

Study design: Phase-I/II, prospective, randomized, single-blind, controlled pilot study. Primary Objective: To determine the safety and feasibility of autologous bone marrow transplantation in patients with acute spinal cord injury (SCI) via two routes of transplantation as compared with controls. Setting: Indian Spinal Injuries Center, New Delhi. Methods: Twenty-one subjects with acute, American Spinal Injury Association Impairment Scale (AIS) A (complete), traumatic SCI with neurological level T1-T12, were recruited and randomized into three groups of seven subjects each. Two groups underwent cell transplantation through the intrathecal or intralesional route, whereas the third served as control. Participants were assessed at baseline and followed up at 6 months and 12-months post enrollment. Safety and tolerability were evaluated by monitoring for any adverse events. Efficacy was assessed through neurological, functional and psychological evaluation, as well as through electrophysiological studies and urodynamics. Results: Surgery was tolerated well by all participants. There were no significant adverse events attributable to the procedure. There was no significant improvement in the neurological, electrophysiological or urodynamic efficacy variables. A statistically significant improvement in functional scores as evaluated by the Spinal Cord Independence Measure and International Spinal Cord Injury Scale was observed in all groups. Conclusions: The procedure is safe and feasible in AIS A participants with thoracic-level injuries at 12-months follow-up. No efficacy could be demonstrated that could be attributed to the procedure.

show abstract

Section: Discussioncontrasting

confidence: 41%

Section: Discussionmentioning

confidence: 99%

Autologous bone marrow cell transplantation in acute spinal cord injury—an Indian pilot study

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Mackay-Sim et al 55 have used a single intraoperative injection. However, other authors 56,57 have performed cellular transplantation in three cycles; in each cycle, five intrathecal injections have been given at 2-11-day intervals. A fourth unresolved issue is whether to obtain stem cells from patients with spinal cord injury or from healthy volunteers.…”

Section: Amr Et Al Bridging Defects With Nerve Grafts and Stem Cellsmentioning

confidence: 99%

Bridging defects in chronic spinal cord injury using peripheral nerve grafts combined with a chitosan-laminin scaffold and enhancing regeneration through them by co-transplantation with bone-marrow-derived mesenchymal stem cells: Case series of 14 patients

Amr

Gouda

Koptan

et al. 2013

The Journal of Spinal Cord Medicine

View full text Add to dashboard Cite

Objective: To investigate the effect of bridging defects in chronic spinal cord injury using peripheral nerve grafts combined with a chitosan-laminin scaffold and enhancing regeneration through them by co-transplantation with bone-marrow-derived mesenchymal stem cells. Methods: In 14 patients with chronic paraplegia caused by spinal cord injury, cord defects were grafted and stem cells injected into the whole construct and contained using a chitosan-laminin paste. Patients were evaluated using the International Standards for Classification of Spinal Cord Injuries. Results: Chitosan disintegration leading to post-operative seroma formation was a complication. Motor level improved four levels in 2 cases and two levels in 12 cases. Sensory-level improved six levels in two cases, five levels in five cases, four levels in three cases, and three levels in four cases. A four-level neurological improvement was recorded in 2 cases and a two-level neurological improvement occurred in 12 cases. The American Spinal Impairment Association (ASIA) impairment scale improved from A to C in 12 cases and from A to B in 2 cases. Although motor power improvement was recorded in the abdominal muscles (2 grades), hip flexors (3 grades), hip adductors (3 grades), knee extensors (2-3 grades), ankle dorsiflexors (1-2 grades), long toe extensors (1-2 grades), and plantar flexors (0-2 grades), this improvement was too low to enable them to stand erect and hold their knees extended while walking unaided. Conclusion: Mesenchymal stem cell-derived neural stem cell-like cell transplantation enhances recovery in chronic spinal cord injuries with defects bridged by sural nerve grafts combined with a chitosan-laminin scaffold.

show abstract

“…In a case report, Ichim et al 11 transplanted a combination of CD34 and placenta-derived MSCs intrathecally into a 29-year-old man with ASIA Grade A SCI after a plane crash. Serial transplantations were performed and were observed to subsequently lead to an improvement in ASIA grade (from Grade A to D) and neuropathic pain (10/10 to 3/10 consistently) over a 1-year follow-up period.…”

Section: Spinal Cord Injurymentioning

confidence: 99%

Potential role of stem cells for neuropathic pain disorders

Vadivelu

Willsey

Curry

et al. 2013

FOC

View full text Add to dashboard Cite

Chronic neuropathic pain is a debilitating disease process associated with several medical disorders. Different from pain caused by inflammation, neuropathic pain is a diffuse pain disorder often found to be recalcitrant to the limited medical treatments available. Intractable nerve pain may benefit from other therapies capable of longer-lasting pain coverage or greater efficacy. A growing number of reports have emerged suggesting a role for stem cells as a cellular delivery source with neuroprotective agents opposing the effects of nerve damage. Here, the authors review the current experimental therapies examining the use of stem cells for the treatment of neuropathic pain disorders.

show abstract

Feasibility of combination allogeneic stem cell therapy for spinal cord injury: a case report

Cited by 80 publications

References 109 publications

Autologous bone marrow cell transplantation in acute spinal cord injury—an Indian pilot study

Autologous bone marrow cell transplantation in acute spinal cord injury—an Indian pilot study

Bridging defects in chronic spinal cord injury using peripheral nerve grafts combined with a chitosan-laminin scaffold and enhancing regeneration through them by co-transplantation with bone-marrow-derived mesenchymal stem cells: Case series of 14 patients

Potential role of stem cells for neuropathic pain disorders

Contact Info

Product

Resources

About